TL;DR
Our GLP-1 lawsuit 2026 review found personal-injury cases pending in federal and state proceedings. These cases include allegations involving serious gastrointestinal injuries and vision loss. An MDL is not a class action, and court coordination does not establish that a drug caused an injury. As of our November 4, 2026 review, the cited sources reported no court-approved global settlement. Anyone experiencing severe stomach symptoms or sudden vision changes should seek medical care before considering legal questions.
GLP-1 lawsuit 2026: current status and last verified update

Last checked: November 4, 2026.
Federal and state courts are coordinating some claims involving GLP-1 drugs. The allegations include severe gastrointestinal injuries and vision loss. Coordination allows courts to manage common pretrial work more efficiently. It does not decide whether a particular drug caused an injury.
A litigation summary dated August 1, 2026 reported no global GLP-1 settlement and no certified Ozempic personal-injury class action. Other 2026 reporting described federal and state coordination of vision-loss and gastrointestinal claims. Unless the parties settle, allegations remain unproven until a court or jury decides them.
| Court or system | Case or proceeding | Docket number | Proceeding type | Reported 2026 status | Source |
|---|---|---|---|---|---|
| U.S. District Court, Eastern District of Pennsylvania | In re GLP-1 Receptor Agonists Products Liability Litigation | MDL No. 3094 | Federal MDL involving gastrointestinal injury claims | Coordinated pretrial proceeding | Judicial Panel on Multidistrict Litigation and PACER Case Locator |
| Federal court system | GLP-1 vision-loss proceeding | MDL No. 3163 | Federal coordinated proceeding concerning NAION allegations | Coordination reported in 2026; individual events require docket review | Judicial Panel on Multidistrict Litigation and PACER Case Locator |
| New Jersey Superior Court | In re GLP-1 Receptor Agonist Litigation | MCL Case No. 643 | State multicounty litigation | State coordination reported for related claims | New Jersey Courts |
This table identifies coordinated proceedings, not every individual lawsuit. It also does not identify winners or predict outcomes. Court schedules and case status can change, so we recommend checking the relevant docket for the latest entries.
The number of filed cases does not establish the strength or value of any claim. Each case may depend on the product used, the diagnosis, treatment dates, warning language, medical history, expert evidence, causation and documented losses.
How to read the court status table
- Filed means a court received a complaint or another document.
- Pending means the court has not entered a final disposition.
- Dismissed means the court ended some or all claims, sometimes with permission to amend them.
- Remanded means a transferred federal case returned to its original court for further proceedings.
- Settled means the parties resolved a claim on agreed terms, which may remain confidential.
- Trial date means a trial is scheduled, not that it will necessarily begin on that date.
A scheduling order sets deadlines. It is not a ruling that a warning was inadequate or that a drug caused an injury. Readers can check the JPML for transfer orders and PACER for federal docket entries.
What changed in the latest update
Our review identified these dated developments:
- January 30, 2026: Published reporting described federal and state coordination of claims alleging NAION and serious stomach injuries.
- August 1, 2026: A reviewed litigation source reported no global GLP-1 settlement and no certified Ozempic personal-injury class action.
- November 1, 2026: A reviewed legal page continued to describe Saxenda-related NAION claims as allegations rather than adjudicated facts.
- November 4, 2026: Our review of the cited sources found no reported court-approved global settlement.
If we identify an error in a docket number, status or date, we will correct it and state when the correction was made.
Is the weight loss drug litigation a class action, MDL, or individual lawsuit?
“Weight loss drug class action” is often an inaccurate label for personal-injury litigation. Many GLP-1 claims remain individual cases even when a federal court coordinates discovery, expert disputes and pretrial motions.
An MDL does not combine every plaintiff into one claimant. State coordination follows its own rules, while a class action requires a court to certify a defined group.
Class action
In a class action, named plaintiffs seek relief for a broader group whose claims share common issues. A court must determine whether the proposed class satisfies the applicable certification rules.
If a class is certified, eligible people generally receive information about the case, their rights and any proposed resolution. The court must approve a class settlement. A headline using the phrase “Ozempic class action lawsuit” does not prove that certification occurred.
Multidistrict litigation and state coordination
The JPML may transfer federal cases with shared factual questions to one judge for coordinated pretrial proceedings. The assigned court can manage discovery, motions, expert evidence and possible test cases.
Plaintiffs still have separate medical histories, injuries, expenses and claimed damages. Cases that neither settle nor end during pretrial proceedings may return to their original courts. State multicounty litigation can coordinate related cases under different procedures and deadlines.
Individual product-liability case
An individual claim may depend on:
- The exact drug and manufacturer
- Whether the use was approved or off-label
- Dose and treatment dates
- Warnings in effect during treatment
- Medical history and other medications
- The diagnosis and when it occurred
- Evidence supporting or disputing causation
- Medical expenses, lost income and other alleged losses
Coordination creates a shared process for common issues. It does not guarantee compensation or establish liability.
Which GLP-1 drugs and injuries do the lawsuits cover?

“GLP-1 lawsuit” is too broad to identify a specific claim. Semaglutide, tirzepatide and liraglutide are different active ingredients. Their brands, manufacturers, approved uses and prescribing information also differ.
Our GLP-1 medications list by active ingredient can help patients identify a product before assessing a lawsuit report.
| Active ingredient | Brands | Maker | Approved use, in brief | Injuries alleged in reviewed coverage | Reported proceeding or status |
|---|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Novo Nordisk | Uses vary by brand and current label | Gastroparesis, prolonged vomiting, obstruction or ileus, related complications, and NAION or vision loss | Federal and state coordinated claims; product coverage varies |
| Tirzepatide | Mounjaro, Zepbound | Eli Lilly | Type 2 diabetes or chronic weight management, depending on brand | Severe gastrointestinal injuries; some broader GLP-1 claims may mention vision injury | Product-specific allegations require complaint review |
| Liraglutide | Victoza, Saxenda | Novo Nordisk | Type 2 diabetes or chronic weight management, depending on brand | NAION or vision loss allegations and gastrointestinal claims in some filings | Individual or coordinated claims may differ by court |
The table summarizes allegations reported in the reviewed sources. It does not mean every brand appears in every proceeding or that the alleged injuries have been proven.
Severe gastrointestinal injury allegations
Some complaints allege gastroparesis, persistent vomiting, intestinal obstruction or ileus, and complications such as dehydration. Gastroparesis involves delayed movement of food from the stomach, but symptoms alone do not establish a diagnosis.
Nausea, vomiting, diarrhea and constipation may appear in GLP-1 prescribing information. A recognized side effect is not necessarily the same as a diagnosed severe injury. We recommend checking the exact product’s current medication guide and the FDA drug database rather than relying on lawsuit advertising for medical guidance.
Vision-loss and NAION allegations
Nonarteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve is disrupted. It can cause sudden and often painless vision loss.
Complaints allege connections between certain GLP-1 products and NAION. Those allegations do not establish causation. Research associations, FDA reviews, prescribing information and court findings are different forms of evidence and should not be treated as interchangeable.
Sudden vision loss, a dark area in someone’s vision or another sharp change in sight requires urgent medical assessment.
Other claims and limits of this review
Reports may also discuss gallbladder disease, pancreatitis, bowel problems or related complications. We do not treat every adverse-event report as a filed lawsuit or every reported symptom as a confirmed drug injury.
A reliable review should connect an alleged injury to a named complaint, court docket, FDA source or current prescribing document. It should also identify the exact product rather than treating every GLP-1 medication as the same.
Lawsuit claim, study finding, FDA action, or proven causation?
We use four evidence labels when reviewing GLP-1 claims:
- Allegation: Someone claims that a product caused harm.
- Association: A study reports a statistical relationship in the population examined.
- Regulatory action: The FDA changes a label, issues a notice or takes another official step.
- Legal finding: A court or jury resolves an issue under the applicable evidence and legal standards.
Taking a drug before a diagnosis establishes timing. By itself, that sequence does not prove medical or legal causation.
An FDA adverse-event report may help identify a possible safety signal. Such reports can lack complete medical information and do not, on their own, show that a product caused an event.
An allegation starts a case
Evidence label: Allegation. A complaint states what the plaintiff says happened. The defendant may dispute the product used, warning language, diagnosis, timing, causation or claimed damages.
Filing a complaint does not create a safety verdict. A court may later dismiss claims, permit amendments, admit or exclude expert evidence, or allow unresolved issues to proceed to trial.
A scientific association is not proof for one patient
Evidence label: Association. A careful study review should consider the design, comparison group, measured outcome, follow-up period and stated limitations. Those details determine what the research can reasonably support.
An association across a study population does not diagnose an individual patient. A clinician must consider symptoms, records, other medications, existing risk factors and alternative explanations.
Regulatory actions and court findings answer different questions
Evidence label: Regulatory action. FDA labels and safety communications provide regulated product information. They can guide prescribing and patient care, but they do not decide civil liability.
Evidence label: Legal finding. Courts apply legal and evidentiary rules to a specific record. A procedural ruling may determine what evidence can be used without deciding whether a drug caused an individual plaintiff’s injury.
Branded GLP-1 drugs and compounded prescriptions are not interchangeable
Compounded semaglutide is not Ozempic or Wegovy. Compounded tirzepatide is not Mounjaro or Zepbound. Referring to the same active ingredient does not make branded and compounded products legally, medically or operationally identical.
The manufacturer, pharmacy, prescriber, formulation, label, container, batch records and supply chain may differ. Litigation can also involve separate issues, including personal injury, marketing, intellectual property or pharmacy practices.
A lawsuit naming a branded drug does not automatically include a compounded prescription.
How to identify the product received
We recommend checking and preserving:
- The prescription label and active ingredient
- The dispensing pharmacy and prescriber
- Concentration and prescribed dose
- Order number, receipt and dispensing date
- Vial, pen, box and instructions
- Lot or batch number, if available
- Clear photographs of every side of the packaging
Record whether the label lists semaglutide, tirzepatide, liraglutide or another ingredient. Follow any recall instructions issued by a clinician, pharmacy, manufacturer or regulator.
Why the legal paths can differ
Potential claims depend on who made, prescribed, dispensed, labeled and marketed a product. The FDA approval and prescribing information for a brand do not automatically describe a compounded preparation.
At usetemi.com, we can help patients locate treatment records held through our care platform. We cannot determine lawsuit eligibility or provide legal advice. That assessment requires a licensed attorney.
Has an Ozempic or GLP-1 settlement been reached?
Settlement status checked November 4, 2026: The reviewed sources did not report a court-approved global settlement covering GLP-1 personal-injury claims. The litigation summary dated August 1, 2026 also reported no global settlement.
We therefore do not publish an average Ozempic lawsuit payout. An eye-catching settlement figure is not reliable unless it connects to a genuine court filing, approval order, authorized administrator, covered group and claim deadline.
Verdicts, private settlements, proposed settlements and global resolutions are different. Advertising estimates and social media posts are not substitutes for official records.
How to verify a settlement claim
Look for all of the following:
- Case name and court
- Docket number
- Settlement agreement or filing
- Preliminary and final approval orders, when applicable
- Authorized administrator
- Eligible class or claimant definition
- Filing and objection deadlines
- Appeal status
Check PACER, the relevant state docket and the authorized administrator’s website. We treat dollar figures without supporting records as unverified.
Why “average payout” tables mislead
A gross settlement fund is not the amount each person receives. Legal fees, case expenses, medical liens, payment tiers, proof requirements, injury severity and claimant numbers can affect net payments.
An MDL case count cannot establish future settlement value either. Individual cases may involve different products, diagnoses, evidence, treatment periods and outcomes.
When might the litigation end?
There is no verified end date. Discovery, expert challenges, motions, trial selection, trials, appeals and individual medical questions can extend litigation.
A scheduled conference or filing deadline is not a settlement date. We will update this section when a court docket or official notice supports a material change.
What to do about severe stomach symptoms or sudden vision changes
Medical care comes first. Seek emergency assessment for:
- Sudden vision loss or a major change in sight
- Severe or worsening abdominal pain
- Repeated vomiting and an inability to keep fluids down
- Fainting or confusion
- Signs of severe dehydration
- Any other acute or rapidly worsening symptom
Contact the prescribing clinician promptly about persistent or concerning symptoms. Do not stop, restart or change a prescribed GLP-1 dose without instructions from a licensed clinician, unless emergency medical staff direct otherwise.
For product-specific information, patients can review our guide to the side effects of Zepbound. Anyone considering a treatment change can also read how to stop taking semaglutide safely before confirming a plan with their prescriber.
Information to give the clinician
Provide:
- Exact product and source
- Current dose and dose-change dates
- Date and amount of the last dose
- When symptoms began and how they changed
- Other prescriptions and supplements
- Diagnoses, imaging, eye exams or procedures
- Emergency visits or hospital admissions
Bring the label or packaging when it is safe and practical. Photographs may help if the original container is unavailable.
FDA labels, medication guides, and adverse-event reports
Current branded prescribing information and medication guides are available through Drugs@FDA. Search for the exact brand rather than the drug class alone.
Patients and clinicians can report suspected adverse events through FDA MedWatch. A MedWatch report can support safety monitoring, but it does not prove causation.
Records to keep when using a branded or compounded GLP-1
Accurate records support medical care and product identification. They do not guarantee that someone has a viable lawsuit.
Keep original labels, messages, photographs and files without changing their dates or contents. Some records may need to be requested from a prescriber, pharmacy, hospital, laboratory, eye clinic or insurer.
Product and prescription records
Record:
- Brand or compounded product name
- Active ingredient and concentration
- Dose and method of administration
- Start date, dose changes and stop date
- Prescriber and dispensing pharmacy
- Prescription or order number
- Dispensing dates and receipts
- Lot or batch information, if available
Keep the vial, pen, box, label and instructions when safe. Take clear photographs before discarding any packaging.
Symptom and treatment records
Create a factual timeline covering symptoms, calls, appointments, tests, diagnoses, treatments, procedures and missed work.
Preserve portal messages, visit summaries, hospital records, imaging reports, eye examination results, medication lists and discharge instructions. Never delay medical care to collect documents.
FAQ
Which is safer, Mounjaro or Ozempic?
There is no single answer for every patient. Mounjaro contains tirzepatide, while Ozempic contains semaglutide. Their approved uses, dosing, contraindications and warnings differ. A licensed prescriber should compare the current labels with the patient’s medical history, medications, treatment goals and previous side effects.
Why are people stopping Ozempic?
People may stop because of side effects, cost, access, treatment goals, pregnancy planning, clinician advice or personal preference. Lawsuit advertising does not prove that Ozempic is unsafe for a particular patient. We recommend discussing the risks and next steps with the prescribing clinician before changing treatment.
What is the average payout per person in a class action?
No reliable average exists without a final settlement, payment rules and claimant data. Class-action payments also differ from individual injury settlements and MDL resolutions. Fees, expenses, liens, payment tiers and claimant numbers can reduce gross amounts. Verify quoted figures through the court docket and authorized administrator.
Is there a lawsuit involving metformin?
Metformin is not a GLP-1 drug. Any metformin case must be assessed according to the specific product, manufacturer, alleged defect, recall, defendant and court. Metformin litigation does not determine the status of proceedings involving Ozempic, Mounjaro, Wegovy, Zepbound or Saxenda.
Can Reddit, television news, or a law-firm update confirm a settlement?
No. Those sources may alert readers to a possible development, but confirmation requires an official court docket, signed approval order or authorized settlement notice. As of our November 4, 2026 review, the cited sources did not report a global GLP-1 personal-injury settlement.
Review your GLP-1 treatment with a clinician
Severe or sudden symptoms require urgent medical care. For routine treatment questions, prescription records or refill support, visit usetemi.com to connect with our care platform and review your treatment with a licensed clinician.




